0001517022-26-000038
SEC filingAkebia Therapeutics reported Q1 2026 net loss of $9.1 million, driven by lower total revenues ($53.5M vs $57.3M YoY) and higher expenses, as Vafseo® revenues grew to $15.8M while Auryxia® revenues declined to $36.2M amid expanding generic competition.
Akebia’s Q1 2026 results reflect a strategic inflection point: accelerating commercial adoption of Vafseo—now generating $15.8M in net product revenue—offset only partially by steep Auryxia decline ($36.2M vs $43.8M YoY) amid intensifying generic pressure, which management explicitly forecasts will further erode Auryxia revenue in 2026. The 60% quarter-over-quarter increase in treated patients and record new-patient starts—concentrated in March—signal improving access and adherence, particularly under observed dosing protocols adopted by dialysis organizations beyond U.S. Renal Care. However, gross margin pressure emerged: COGS more than doubled to $12.3M (vs $7.6M YoY), driven by inventory write-downs, though Vafseo-related COGS remains artificially low due to pre-launch inventory accounting. R&D spend rose 51% YoY to $14.8M, reflecting active pipeline advancement—including first patient dosed in the praliciguat Phase 2 FSGS trial and initiation of the AKB-9090 Phase 1 study—while SG&A increased 18% YoY to $30.4M, mainly from headcount growth. The swing from $6.1M net income in Q1 2025 to a $9.1M net loss underscores the transitional cost of scaling commercial infrastructure and clinical development ahead of anticipated data catalysts: VOCAL Phase 3b topline in Q4 2026 and VOICE Phase IV topline in early 2027. With $162.6M in cash and a two-year runway affirmation, Akebia is prioritizing evidence generation and pipeline execution over near-term profitability—a high-stakes bet on Vafseo becoming standard-of-care and next-generation assets delivering validation in rare kidney diseases.